FT. LAUDERDALE, Fla.--(EON: Enhanced Online News)--Puget Technologies (OTCBB:PUGE) announced its subsidiary, Cannabis Biotech, is in talks with a research chemist to explore the development of an exclusive cannabis-based metered-dose transmucosal delivery platform. The transmucosal system is an effective means to introduce treatments across the mucous membrane and is a well-established and accepted system of administration. Cannabis Biotech sought out this eminently qualified professional in the beginning stages as it enters the multi-billion dollar medical marijuana industry with a commitment to maintaining strict protocols and quality standards.
“We are looking forward to this eminent scientist joining our research team. This will bring us one step closer to our goal of providing patients with products developed under the most rigorous standards and protocols.”
This project is part of the company’s strategy to develop a wider variety of delivery methods directed towards a growing, diverse patient base. Cannabis Biotech’s research is focusing on the growing number of patients who desire the benefits of medical marijuana but do not want the harmful effects or stigma of smoking it.
According to one estimate, there are 24.8 million potential patients eligible for medical marijuana (The State of Marijuana Markets 2011). Currently 20 U.S. states and the District of Columbia have enacted laws to legalize the use of medical marijuana.
President and CEO of Puget Technologies Ron Leyland said, “We are looking forward to this eminent scientist joining our research team. This will bring us one step closer to our goal of providing patients with products developed under the most rigorous standards and protocols.”
The uptake of medicine via transmucosal systems is well received by patients. Flonase (fluticasone propionate) manufactured by GlaxoSmithKline (NYSE: GSK), Rhinocort Aqua (budesonide) by AstraZeneca (NYSE: AZN), and Nicotrol®NS (nicotine nasal spray) by Pfizer (NYSE: PFE) are popular medications which are commonly used in the U.S. The methodology is used as an anti-influenza therapy and to treat allergies, vitamin B deficiency, osteoporosis and nicotine addiction among other conditions.
More information about Cannabis Biotech can be found at http://www.cannabisbiotech.com.
About Puget Technologies (PUGE)
Puget Technologies is a publicly traded company on the OTCBB Market stock exchange under the ticker symbol PUGE. Headquartered in Ft. Lauderdale, Florida, Puget Technologies acquires, develops and sells leading edge consumer oriented products ready for rapid commercialization. Puget plans to become a recognized market leader in its product categories. Much of its resources are dedicated to research and development in order to provide consumers with quality options while meeting the expectations of its investors.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.